Squarepoint
IKT icon

Squarepoint’s Inhibikase Therapeutics IKT Stock Holding History

Squarepoint’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$26.1K Sell
12,854
-18,135
-59% -$32.5K ﹤0.01% 4303
2026
Q1 		$52.1K Buy
+30,989
New +$55K ﹤0.01% 4137
2025
Q1 		– Sell
-28,411
Closed -$92.3K – 4972
2024
Q4 		$92.3K Buy
+28,411
New +$70.9K ﹤0.01% 4722

Other funds holding IKT

SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Squarepoint's IKT Position: Q2 2026 in Review

Squarepoint reduced its Inhibikase Therapeutics (IKT) stake by 59% in Q2 2026, selling an estimated $32.5K and leaving 12,854 shares worth $26.1K. The position accounts for ﹤0.01% of the portfolio, ranked #4303.

Squarepoint first reported a position in IKT in Q4 2024 and has held it in 3 quarters since. The position peaked at $92.3K in Q4 2024. 98 funds tracked by Wall St. Rank hold IKT as of Q2 2026.

  • Squarepoint held 12,854 shares of Inhibikase Therapeutics worth $26.1K as of Q2 2026.
  • Squarepoint sold 18,135 Inhibikase Therapeutics shares in Q2 2026, an estimated $32.5K.
  • Inhibikase Therapeutics made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #4303 holding.
  • Squarepoint first reported a position in Inhibikase Therapeutics in Q4 2024 and has held it in 3 quarters since.
  • Squarepoint's Inhibikase Therapeutics position peaked at $92.3K in Q4 2024.
  • 98 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.